SG Americas Securities LLC Takes Position in Grifols, S.A. $GRFS

SG Americas Securities LLC purchased a new stake in Grifols, S.A. (NASDAQ:GRFS) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 112,138 shares of the biotechnology company’s stock, valued at approximately $1,048,000.

A number of other institutional investors have also modified their holdings of GRFS. Versant Capital Management Inc boosted its stake in Grifols by 39.5% in the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,584 shares in the last quarter. Merit Financial Group LLC raised its position in Grifols by 14.1% during the 3rd quarter. Merit Financial Group LLC now owns 13,978 shares of the biotechnology company’s stock worth $139,000 after buying an additional 1,728 shares during the last quarter. Savant Capital LLC raised its position in Grifols by 16.0% during the 3rd quarter. Savant Capital LLC now owns 14,011 shares of the biotechnology company’s stock worth $140,000 after buying an additional 1,935 shares during the last quarter. Ascent Group LLC raised its position in Grifols by 12.5% during the 3rd quarter. Ascent Group LLC now owns 17,597 shares of the biotechnology company’s stock worth $175,000 after buying an additional 1,951 shares during the last quarter. Finally, Creative Planning raised its position in Grifols by 15.0% during the 3rd quarter. Creative Planning now owns 16,414 shares of the biotechnology company’s stock worth $163,000 after buying an additional 2,141 shares during the last quarter.

Grifols Stock Performance

GRFS opened at $8.39 on Thursday. Grifols, S.A. has a 12-month low of $6.19 and a 12-month high of $11.14. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $5.71 billion, a PE ratio of 44.16, a P/E/G ratio of 0.29 and a beta of 0.70. The firm has a 50 day moving average of $8.63 and a two-hundred day moving average of $8.97.

Grifols (NASDAQ:GRFS) last posted its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The firm had revenue of $2.32 billion during the quarter. Grifols had a net margin of 6.65% and a return on equity of 6.23%. On average, analysts anticipate that Grifols, S.A. will post 0.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GRFS. Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Finally, Wall Street Zen raised shares of Grifols from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.